Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.53 |
| ▸ | FAP | Q12884 | 7/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516850 | 1.00 | DPP4 (0.53) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL13738693 | 0.89 | DPP4 (0.45) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15533174 | 0.88 | DPP4 (0.53) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15533200 | 0.82 | DPP4 (0.42) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15533388 | 0.81 | DPP4 (0.47) | DPP4 | |
| SCHEMBL16794573 | 0.80 | DPP4 (0.46) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15533861 | 0.79 | DPP4 (0.43) | DPP4KCNH2 | |
| SCHEMBL23111991 | 0.74 | DPP4 (0.49) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15091721 | 0.72 | DPP4 (0.34) | DPP4 | |
| SCHEMBL12047730 | 0.71 | DPP4 (0.84) | DPP4FAPCHRM1POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3996704-A1 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | MANKIND PHARMA LTD (IN) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021005436-A1 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | MANKIND PHARMA LTD. (IN) | 2021-01-14 | — | — | WO | disclosed |
| EP-2854824-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2014193528-A1 | AMORPHOUS DOSAGE FORMS AND METHODS | ANOVEL PHARMACEUTICALS, LLC (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014074668-A1 | MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013174769-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-28 | — | — | WO | disclosed |
| EP-2619198-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2611433-A2 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611782-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611781-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012145604-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145603-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012135570-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012040279-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012030951-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030957-A2 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030938-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |